Examples of basket trials include a study of imatinib in multiple histological subtypes of advanced sarcoma [7], a study of vemurafenib in BRAF V600 mutation-positive non-melanoma cancers [8], and a study of larotrectinib in TRK fusion-positive cancers [9], among others. Here, BRAF is linked to melanoma.